Joseph Schwartz
Stock Analyst at Leerink Partners
(4.93)
# 184
Out of 4,455 analysts
1310
Total ratings
53.5%
Success rate
31%
Average return
Main Sectors:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $4 | $0.9435 | +323.95% | 1 | Jun 24, 2026 | |
| QURE uniQure | Reiterated: Buy | $60 → $70 | $47.51 | +47.34% | 62 | Jun 17, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | $52 | $41.46 | +25.42% | 50 | Jun 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $88 → $95 | $36.70 | +158.86% | 46 | Jun 11, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $225 → $305 | $260.75 | +16.97% | 72 | Jun 2, 2026 | |
| FULC Fulcrum Therapeutics | Downgraded: Hold | $24 → $4 | $3.80 | +5.26% | 37 | Jun 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Hold | $60 → $62 | $59.00 | +5.08% | 90 | May 18, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $160 → $120 | $55.11 | +117.75% | 32 | May 15, 2026 | |
| ANTX AN2 Therapeutics | Upgraded: Buy | $1 → $9 | $5.20 | +73.08% | 23 | May 15, 2026 | |
| RNA Atrium Therapeutics | Initiated Coverage: Buy | $25 | $13.19 | +89.54% | 1 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28.38 | $10.20 | +178.23% | 1 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 → $25 | $5.83 | +328.82% | 31 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $16.85 | -10.98% | 107 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $28.43 | +75.87% | 9 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 | $0.157 | +3,721.66% | 35 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $58.85 | - | 87 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $30.77 | - | 69 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $34.01 | +11.73% | 37 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.92 | - | 50 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $2 | $0.2966 | +574.31% | 31 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $9.29 | +115.29% | 45 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $16 | $17.23 | -7.14% | 52 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $5 → $14 | $13.35 | +4.87% | 29 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $115 | $87.68 | +31.16% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $54 | $84.43 | -36.04% | 33 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $103.38 | - | 63 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.66 | +583.06% | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.70 | +488.24% | 29 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $0.68 | n/a | 29 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.50 | n/a | 19 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $14 | $215.75 | n/a | 1 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $150 → $30 | $9.42 | n/a | 10 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 → $34 | $81.18 | n/a | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $121.88 | n/a | 28 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $358.33 | n/a | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.69 | n/a | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $31 → $4 | $50.08 | n/a | 16 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $329.05 | n/a | 1 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $53.92 | $237.78 | n/a | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $30 | $1.08 | n/a | 2 | Jan 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 → $23 | $16.68 | n/a | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $12 | $1.53 | n/a | 5 | Sep 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $121 → $126 | $542.66 | n/a | 4 | Apr 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $16.01 | n/a | 11 | Nov 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.0623 | n/a | 5 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $7.06 | n/a | 6 | Nov 10, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.8885 | n/a | 1 | Mar 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $664 | $632.90 | n/a | 7 | Oct 26, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $512 → $425 | $216.03 | n/a | 3 | Sep 15, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $8 | $82.19 | n/a | 3 | May 19, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $15.91 | n/a | 6 | Oct 30, 2013 |
Quince Therapeutics
Jun 24, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $0.9435
Upside: +323.95%
uniQure
Jun 17, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $47.51
Upside: +47.34%
Edgewise Therapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $52
Current: $41.46
Upside: +25.42%
Crinetics Pharmaceuticals
Jun 11, 2026
Maintained: Buy
Price Target: $88 → $95
Current: $36.70
Upside: +158.86%
Ascendis Pharma
Jun 2, 2026
Reiterated: Buy
Price Target: $225 → $305
Current: $260.75
Upside: +16.97%
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $24 → $4
Current: $3.80
Upside: +5.26%
BioMarin Pharmaceutical
May 18, 2026
Reiterated: Hold
Price Target: $60 → $62
Current: $59.00
Upside: +5.08%
Spruce Biosciences
May 15, 2026
Reiterated: Buy
Price Target: $160 → $120
Current: $55.11
Upside: +117.75%
AN2 Therapeutics
May 15, 2026
Upgraded: Buy
Price Target: $1 → $9
Current: $5.20
Upside: +73.08%
Atrium Therapeutics
May 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.19
Upside: +89.54%
Apr 6, 2026
Initiated Coverage: Buy
Price Target: $28.38
Current: $10.20
Upside: +178.23%
Mar 26, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $5.83
Upside: +328.82%
Mar 25, 2026
Maintained: Hold
Price Target: $15
Current: $16.85
Upside: -10.98%
Mar 25, 2026
Reiterated: Buy
Price Target: $50
Current: $28.43
Upside: +75.87%
Feb 23, 2026
Downgraded: Hold
Price Target: $6
Current: $0.157
Upside: +3,721.66%
Jan 13, 2026
Maintained: Buy
Price Target: n/a
Current: $58.85
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $30.77
Upside: -
Jan 13, 2026
Reiterated: Buy
Price Target: $38
Current: $34.01
Upside: +11.73%
Dec 31, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.92
Upside: -
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $2
Current: $0.2966
Upside: +574.31%
Dec 15, 2025
Reiterated: Buy
Price Target: $20
Current: $9.29
Upside: +115.29%
Dec 3, 2025
Downgraded: Hold
Price Target: $12 → $16
Current: $17.23
Upside: -7.14%
Dec 3, 2025
Upgraded: Buy
Price Target: $5 → $14
Current: $13.35
Upside: +4.87%
Nov 10, 2025
Initiated Coverage: Buy
Price Target: $115
Current: $87.68
Upside: +31.16%
Oct 16, 2025
Reiterated: Hold
Price Target: $54
Current: $84.43
Upside: -36.04%
Sep 29, 2025
Reiterated: Buy
Price Target: n/a
Current: $103.38
Upside: -
Aug 15, 2025
Reiterated: Buy
Price Target: $25
Current: $3.66
Upside: +583.06%
Aug 7, 2025
Maintained: Buy
Price Target: $10
Current: $1.70
Upside: +488.24%
Aug 12, 2024
Reiterated: Hold
Price Target: $1
Current: $0.68
Upside: n/a
May 7, 2024
Reiterated: Hold
Price Target: $10
Current: $4.50
Upside: n/a
Sep 7, 2023
Maintained: Hold
Price Target: $14
Current: $215.75
Upside: n/a
Aug 18, 2023
Downgraded: Hold
Price Target: $150 → $30
Current: $9.42
Upside: n/a
Feb 3, 2023
Maintained: Hold
Price Target: $40 → $34
Current: $81.18
Upside: n/a
Aug 5, 2022
Reiterated: Buy
Price Target: $30
Current: $121.88
Upside: n/a
Aug 4, 2022
Rated: Hold
Price Target: n/a
Current: $358.33
Upside: n/a
Jul 13, 2022
Maintained: Buy
Price Target: n/a
Current: $7.69
Upside: n/a
Apr 5, 2022
Downgraded: Hold
Price Target: $31 → $4
Current: $50.08
Upside: n/a
May 7, 2021
Downgraded: Sell
Price Target: n/a
Current: $329.05
Upside: n/a
Apr 15, 2021
Maintained: Buy
Price Target: $53.92
Current: $237.78
Upside: n/a
Jan 6, 2021
Downgraded: Hold
Price Target: $5 → $30
Current: $1.08
Upside: n/a
Nov 28, 2018
Initiated Coverage: Buy
Price Target: $37 → $23
Current: $16.68
Upside: n/a
Sep 26, 2017
Maintained: Buy
Price Target: $10 → $12
Current: $1.53
Upside: n/a
Apr 3, 2017
Maintained: Hold
Price Target: $121 → $126
Current: $542.66
Upside: n/a
Nov 13, 2016
Reiterated: Buy
Price Target: n/a
Current: $16.01
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $8
Current: $0.0623
Upside: n/a
Nov 10, 2016
Reiterated: Buy
Price Target: $12 → $14
Current: $7.06
Upside: n/a
Mar 8, 2016
Maintained: Buy
Price Target: $24
Current: $0.8885
Upside: n/a
Oct 26, 2015
Reiterated: Buy
Price Target: $664
Current: $632.90
Upside: n/a
Sep 15, 2015
Maintained: Buy
Price Target: $512 → $425
Current: $216.03
Upside: n/a
May 19, 2014
Initiated Coverage: Buy
Price Target: $20 → $8
Current: $82.19
Upside: n/a
Oct 30, 2013
Downgraded: Hold
Price Target: n/a
Current: $15.91
Upside: n/a